
David B Clemow

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9599400/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Effect of a change in lasmiditan dose on efficacy and safety in patients with migraine. Postgraduate Medicine, 2021, 133, 449-459.	0.9	3
2	Lasmiditan in patients with common migraine comorbidities: a <i>post hoc</i> efficacy and safety analysis of two phase 3 randomized clinical trials. Current Medical Research and Opinion, 2020, 36, 1791-1806.	0.9	7
3	Lasmiditan mechanism of action – review of a selective 5-HT1F agonist. Journal of Headache and Pain, 2020, 21, 71.	2.5	74
4	Medical Writing Competency Model — Section 1: Functions, Tasks, and Activities. Therapeutic Innovation and Regulatory Science, 2018, 52, 70-77.	0.8	4
5	Medical Writing Competency Model — Section 2: Knowledge, Skills, Abilities, and Behaviors. Therapeutic Innovation and Regulatory Science, 2018, 52, 78-88.	0.8	3
6	A review of the efficacy of atomoxetine in the treatment of attention-deficit hyperactivity disorder in children and adult patients with common comorbidities. Neuropsychiatric Disease and Treatment, 2017, Volume 13, 357-371.	1.0	35
7	Atomoxetine Increased Effect over Time in Adults with Attentionâ€Deficit/Hyperactivity Disorder Treated for up to 6 Months: Pooled Analysis of Two Doubleâ€Blind, Placeboâ€Controlled, Randomized Trials. CNS Neuroscience and Therapeutics, 2016, 22, 546-557.	1.9	8
8	Clinical Impact of Not Achieving Recommended Dose on Duration of Atomoxetine Treatment in Adults with Attentionâ€Deficit/Hyperactivity Disorder. CNS Neuroscience and Therapeutics, 2016, 22, 970-978.	1.9	1
9	Realâ€World Dosing Patterns of Atomoxetine in Adults with Attentionâ€Deficit/Hyperactivity Disorder. CNS Neuroscience and Therapeutics, 2015, 21, 936-942.	1.9	6
10	Medicines in Pregnancy Forum: Proceedings on Ethical and Legal Considerations. Therapeutic Innovation and Regulatory Science, 2015, 49, 326-332.	0.8	1
11	Misuse of Methylphenidate. Current Topics in Behavioral Neurosciences, 2015, 34, 99-124.	0.8	33
12	Atomoxetine monotherapy compared with combination therapy for the treatment of ADHD: a retrospective chart review study. Expert Review of Neurotherapeutics, 2015, 15, 1353-1366.	1.4	2
13	Atomoxetine treatment in adults with attention-deficit/hyperactivity disorder. Postgraduate Medicine, 2015, 127, 686-701.	0.9	19
14	Atomoxetine in patients with ADHD: A clinical and pharmacological review of the onset, trajectory, duration of response and implications for patients. Journal of Psychopharmacology, 2015, 29, 1221-1230.	2.0	54
15	The Potential for Misuse and Abuse of Medications in ADHD: A Review. Postgraduate Medicine, 2014, 126, 64-81.	0.9	128
16	Clinical Data for Informed Medication Use in Pregnancy: Strengths, Limitations, Gaps, and a Need to Continue Moving Forward. Therapeutic Innovation and Regulatory Science, 2014, 48, 134-144.	0.8	3
17	A Proposed Framework to Address Needs of Clinical Data for Informed Medication Use in Pregnancy. Therapeutic Innovation and Regulatory Science, 2014, 48, 145-154.	0.8	6
18	Suboptimal Dosing of Strattera (Atomoxetine) for ADHD Patients. Postgraduate Medicine, 2014, 126, 197-199.	0.9	10

#	Article	IF	CITATIONS
19	Atomoxetine Effects on Executive Function as Measured by the BRIEF-A in Young Adults with ADHD: A Randomized, Double-Blind, Placebo-Controlled Study. PLoS ONE, 2014, 9, e104175.	1.1	24